更新時間： 2026-08-14 10:08:38
Sionna Therapeutics, Inc. is a pioneering biotechnology firm dedicated to developing cutting-edge therapies for neurodegenerative disorders, specifically targeting conditions such as Alzheimer's and Parkinson's diseases characterized by protein misfolding. With a strong pipeline bolstered by proprietary technologies, the company is positioned to meet significant unmet medical needs in this critical therapeutic area. Sionna’s strategic collaborations and a steadfast commitment to research and development underscore its status as a key player in the biopharmaceutical landscape, aiming to improve patient outcomes and quality of life through innovative neurological solutions.
| 指標 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| 收入 | $0 | $0 | $0 | $0 |
| 經營支出 | $154K | $152K | $100K | $147K |
| 淨收入 | -$26.779M | -$20.44M | -$20.278M | -$18.068M |
| 淨利率 | -- | -- | -- | -- |
| 每股收益 | $-0.60 | $-0.51 | $-0.46 | $-0.41 |
| 息稅折舊攤銷前利潤 | -$26.625M | -$16.76M | -$19.758M | -$17.921M |
| 有效稅率 | -- | -- | -- | -- |
